Balance Sheet (Annual)

HUM / Humana, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 1,377,000 1,306,000 1,138,000 1,935,000 2,571,000 3,877,000 4,042,000
    Available For Sale Securities Debt Securities Current 7,743,000 8,001,000 8,090,000 7,598,000 7,267,000 7,595,000 9,557,000
    Receivables Net Current 1,034,000 733,000 950,000 1,168,000 1,161,000 1,280,000 854,000
    Other Assets Current 1,027,000 1,670,000 2,122,000 4,011,000 4,712,000 3,438,000 2,949,000
    Assets Current 11,181,000 11,710,000 12,300,000 14,712,000 15,711,000 16,190,000 17,402,000
  Property Plant And Equipment Net 912,000 1,098,000 1,218,000 1,419,000 1,384,000 1,505,000 1,584,000
  Available For Sale Securities Debt Securities Noncurrent 1,710,000 1,846,000 1,710,000 1,949,000 1,843,000 2,203,000 2,745,000
  Goodwill 2,740,000 3,640,000 3,733,000 3,711,000 3,265,000 3,272,000 3,281,000
  Other Assets Noncurrent 1,165,000 1,685,000 1,774,000 1,675,000 2,502,000 2,226,000 2,166,000
  Assets 17,708,000 19,979,000 20,735,000 23,466,000 24,705,000 25,396,000 27,178,000
Liabilities And Stockholders Equity
  Liabilities Current
    Liability For Claims And Claims Adjustment Expense 3,754,000 3,779,000 3,893,000 4,475,000 4,976,000 4,563,000 4,668,000
    Accounts Payable And Accrued Liabilities Current 1,783,000 2,042,000 1,821,000 2,185,000 2,212,000 2,467,000 4,069,000
    Other Short Term Borrowings 306,000 324,000 403,000 334,000 301,000 212,000 141,000
    Deferred Revenue Current 213,000 230,000 206,000 361,000 364,000 280,000 378,000
    Short Term Borrowings - - - - 299,000 300,000 150,000
    Liabilities Current 6,056,000 6,375,000 6,323,000 7,355,000 8,152,000 7,822,000 9,406,000
  Long Term Debt Noncurrent 1,659,000 2,611,000 2,600,000 3,825,000 3,821,000 3,792,000 4,770,000
  Liability For Future Policy Benefits 1,663,000 1,858,000 2,207,000 2,349,000 2,151,000 2,834,000 2,923,000
  Other Liabilities Noncurrent 267,000 288,000 289,000 291,000 235,000 263,000 237,000
  Liabilities 9,645,000 11,132,000 11,419,000 13,820,000 14,359,000 14,711,000 17,336,000
  Commitments And Contingencies - - - - - - -
  Stockholders Equity
    Preferred Stock Value 0 0 0 0 0 0 0
    Common Stock Value 32,000 32,000 33,000 33,000 33,000 33,000 33,000
    Additional Paid In Capital Common Stock 1,938,000 2,101,000 2,267,000 2,330,000 2,530,000 2,562,000 2,445,000
    Retained Earnings Accumulated Deficit 6,825,000 7,881,000 8,942,000 9,916,000 11,017,000 11,454,000 13,670,000
    Accumulated Other Comprehensive Income Loss Net Of Tax 303,000 386,000 158,000 223,000 58,000 -66,000 19,000
    Treasury Stock Value 1,035,000 1,553,000 2,084,000 2,856,000 3,292,000 3,298,000 6,325,000
    Stockholders Equity 8,063,000 8,847,000 9,316,000 9,646,000 10,346,000 10,685,000 9,842,000
  Liabilities And Stockholders Equity 17,708,000 19,979,000 20,735,000 23,466,000 24,705,000 25,396,000 27,178,000

Peers - Hospital and Medical Service Plans (6324)

Related Articles

HIMX: Himax Technologies Analysis and Research Report

7h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 444859102